- Home
- SST vs DYAI Comparison
SST vs DYAI Comparison
Compare SST & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SST
- DYAI
- Stock Information
- Founded
- SST 2013
- DYAI 1979
- Country
- SST United States
- DYAI United States
- Employees
- SST N/A
- DYAI N/A
- Industry
- SST Diversified Commercial Services
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SST Consumer Discretionary
- DYAI Health Care
- Exchange
- SST Nasdaq
- DYAI Nasdaq
- Market Cap
- SST 67.8M
- DYAI 54.4M
- IPO Year
- SST N/A
- DYAI 2004
- Fundamental
- Price
- SST $0.61
- DYAI $1.50
- Analyst Decision
- SST Hold
- DYAI Strong Buy
- Analyst Count
- SST 1
- DYAI 1
- Target Price
- SST $2.00
- DYAI $6.00
- AVG Volume (30 Days)
- SST 168.5K
- DYAI 213.3K
- Earning Date
- SST 03-17-2025
- DYAI 11-12-2024
- Dividend Yield
- SST N/A
- DYAI N/A
- EPS Growth
- SST N/A
- DYAI N/A
- EPS
- SST N/A
- DYAI N/A
- Revenue
- SST $364,450,000.00
- DYAI $3,364,548.00
- Revenue This Year
- SST N/A
- DYAI $51.30
- Revenue Next Year
- SST $2.59
- DYAI $73.26
- P/E Ratio
- SST N/A
- DYAI N/A
- Revenue Growth
- SST N/A
- DYAI 13.82
- 52 Week Low
- SST $0.60
- DYAI $0.93
- 52 Week High
- SST $2.73
- DYAI $2.67
- Technical
- Relative Strength Index (RSI)
- SST 31.23
- DYAI 42.12
- Support Level
- SST $0.60
- DYAI $1.45
- Resistance Level
- SST $0.70
- DYAI $1.79
- Average True Range (ATR)
- SST 0.09
- DYAI 0.24
- MACD
- SST -0.02
- DYAI -0.05
- Stochastic Oscillator
- SST 3.18
- DYAI 7.25
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment.
About DYAI Dyadic International Inc.
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.